Precursor lesions and prognostic factors in primary peritoneal serous carcinoma

International Journal of Gynecological Pathology

Volumn 32, Issue 6, 2013, Pages 547-555

  Lee, Sandra ^a   Nelson, Gregg ^a   Duan, Quili ^b   Magliocco, Anthony M ^c   Duggan, Máire A ^a  

^a UNIVERSITY OF CALGARY   (Canada)

^b TOM BAKER CANCER CENTRE   (Canada)

^c H LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE   (United States)

Author keywords

Longitudinal analysis; p16 expression; p53 expression; Primary peritoneal serous carcinoma; Tubal precursors

Indexed keywords

BIOLOGICAL MARKER; CARBOPLATIN; PACLITAXEL; PROTEIN P16; PROTEIN P53;

ABDOMINAL HYSTERECTOMY; CANCER PROGNOSIS; CLINICAL ARTICLE; EPITHELIUM; FEMALE; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; OMENTECTOMY; OUTCOME ASSESSMENT; OVARIAN CORTICAL INCLUSION CYST; OVARIAN SURFACE EPITHELIUM; OVARY CARCINOMA; OVARY CYST; OVERALL SURVIVAL; PAPILLARY CARCINOMA; PERITONEUM CANCER; PRIMARY PERITONEAL SEROUS CARCINOMA; PRIORITY JOURNAL; REVIEW; SALPINGOOOPHORECTOMY; SCORING SYSTEM; STAINING; TUBAL EPITHELIAL ATYPIA CARCINOMA; UTERINE TUBE;

ADULT; AGED; CYSTADENOCARCINOMA, SEROUS; FALLOPIAN TUBES; FEMALE; HUMANS; MIDDLE AGED; NEOPLASM GRADING; OVARY; PERITONEAL NEOPLASMS; PROGNOSIS; TUMOR SUPPRESSOR PROTEIN P53;

EID: 84886007318     PISSN: 02771691     EISSN: 15387151     Source Type: Journal    
DOI: 10.1097/PGP.0b013e31827f3fa8     Document Type: Review

References (26)

1. Kurman RJ, Shih IM. Pathogenesis of ovarian cancer: lessons from morphology and molecular biology and their clinical implications. Int J Gynecol Path 2008;27:151-60. (Pubitemid 351450677)
2. Piek JM, Van Diest PJ, Zweemer RP, et al. Dysplastic changes in the prophylactically removed fallopian tubes of women predisposed to developing ovarian cancer. J Pathol 2001;195: 451-6. (Pubitemid 33069670)
3. Kindelberger DW, Lee Y, Miron A, et al. Intraepithelial carcinoma of the fimbria and pelvic serous carcinoma: evidence for a causal relationship. Am J Surg Pathol 2007;31: 161-9. (Pubitemid 46175016)
4. Crum CP, McKeon FD, BRCA Xian W. The oviduct, and the space and time continuum of pelvic serous carcinogenesis. Int J Gynecol Cancer 2012;22:S29-34.
5. Folkins AK, Jarboe EA, Saleemuddin A, et al. A candidate precursor to pelvic serous cancer (p53 signature) and its prevalence in ovaries and fallopian tubes from women with BRCA mutations. Gynecol Oncol 2008;108:168-73.
6. Crum CP, Xian W. Bringing the p53 signature into focus. Cancer 2010;116:5119-21.
7. Chen LM, Yamada D, Fu YS, et al. Molecular similarities between primary peritoneal and primary ovarian carcinomas. Int J Gynecol Cancer 2003;23:749-55.
8. Kowalski LD, Kanvour AI, Price FV, et al. A case-matched molecular comparison of extraovarian versus primary ovarian adenocarcinoma. Cancer 1997;79:1587-94. (Pubitemid 27154792)
9. Bloss JD, Liao SY, Buller RE, et al. Extraovarian peritoneal serous papillary carcinoma: a case-control retrospective comparison to papillary adenocarcinoma of the ovary. Gynecol Oncol 1993;50:347-51. (Pubitemid 23299731)
10. Jordan SJ, Green AC, Whiteman DC, et al. Serous ovarian, fallopian tube and primary peritoneal cancers: a comparative epidemiological analysis. Int J Cancer 2008;122:1598-603. (Pubitemid 351294969)
11. Fromm GL, Gershenson DM, Silva FG. Papillary serous carcinoma of the peritoneum. Obstet Gynecol 1990;75:89-95. (Pubitemid 20047939)
12. Eltabbakh GH, Werness BA, Piver S, et al. Prognostic factors in extraovarian primary peritoneal carcinoma. Gynecol Oncol 1998;71:230-9. (Pubitemid 28550806)
13. Zhang C, Li X-P, Cui H, et al. Advanced primary peritoneal carcinoma. J Zhejiang Univ Sci B 2008;9:435-40.
14. Look M, Chang D, Sugarbaker PH. Long term results of cytoreductive surgery for advanced and recurrent epithelial ovarian cancers and papillary serous carcinoma of the peritoneum. Int J Gynecol Cancer 2004;14:35-41. (Pubitemid 38280621)
15. Piek JMJ, Kenemans P, Verheijen RHM. Intraperitoneal serous adenocarcinoma: a critical appraisal of three hypotheses on its cause. Am J Obstet Gynecol 2007;191:718-32. (Pubitemid 39298100)
16. Carlson JW, Miron A, Jarboe EA, et al. Serous tubal intraepithelial carcinoma: its potential role in primary peritoneal serous carcinoma and serous cancer prevention. J Clin Oncol 2008;26:4160-5.
17. Seidmen JD, Zhao P, Yemelyanova A. "Primary peritoneal" high-grade serous carcinoma is very likely metastatic from serous tubal intraepithelial carcinoma: assessing the new paradigm of ovarian and pelvic serous carcinogenesis and its implications for screening for ovarian cancer. Gynecol Oncol 2011;120:470-3.
18. Leonhardt K, Einenkel J, Sohr S, et al. p53 signature and tubal in situ carcinoma in cases of primary tubal and peritoneal carcinomas and serous borderline tumors of the ovary. Int J Gynecol Pathol 2011;30:417-24.
19. Kuhn E, Kurman RJ, Vang R, et al. TP53 mutations in serous intraepithelial carcinoma and concurrent pelvic high-grade serous carcinoma-evidence supporting the clonal relationship of the two lesions. J Pathol 2012;226:421-6.
20. Canepa ET, Scassa ME, Ceruti JM, et al. INK4 proteins, a family of mammalian CDK inhibitors with novel biological functions. IUBMB Life 2007;57:419-26. (Pubitemid 47123998)
21. Vang R, Shih I, Kurman RJ. Ovarian low-grade and highgrade serous carcinoma: pathogenesis, clinicopathologic, and molecular biologic features, and diagnostic problems. Adv Anat Pathol 2009;16:267-82.
22. Boenisch T, Farmilo AJ, Stead RH, eds. Handbook: Immu-nochemical Staining Methods.; 3rd ed Carpinteria: DakoCyto-mation Corporation; 2001.
23. Allred DC, Harvey JM, Berardo M, et al. Prognostic and predictive factors in breast cancer by immunohistochemical analysis. Mod Pathol 1998;11:155-68. (Pubitemid 28144151)
24. Kobel M, Reuss A, Bois A, et al. The biological and clinical value of p53 expression in pelvic high grade serous carcinomas. J Pathol 2010;222:191-8.
25. Alkushi A, Koebel M, Kalloger S, et al. High-grade endometrial carcinoma: serous and grade 3 endometrioid carcinomas have different immunophenotypes and outcomes. Int J Gynecol Pathol 2010;29:343-50.
26. Kobel M, Turbin D, Kalloger SE, et al. Biomarker expression in pelvic high-grade serous carcinoma: comparison of ovarian and omental sites. Int J Gynecol Pathol 2011;30: 366-71.